Cord blood cells join fight against stubborn transplant complication
NCT ID NCT04744116
First seen Nov 10, 2025 · Last updated Apr 25, 2026 · Updated 13 times
Summary
This study tests whether adding special cells from donated cord blood to a standard drug (ruxolitinib) can better control severe graft-versus-host disease (GVHD) that hasn't responded to steroids. GVHD is a serious complication where donor immune cells attack the patient's body after a stem cell transplant. The trial involves 24 participants aged 12-80 and aims to see if the combination improves response and reduces side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.